| Q51745715 | Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. |
| Q37846338 | Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning |
| Q33886185 | Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellu |
| Q85536716 | Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse |
| Q98719922 | Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents |
| Q50790069 | Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. |
| Q34549313 | Allogeneic transplantation for chronic lymphocytic leukemia |
| Q36865616 | Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning |
| Q45792752 | An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report. |
| Q45070097 | Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia |
| Q37123927 | Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells |
| Q35848136 | Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia |
| Q41882563 | Boosting leukemia-specific T cell responses in patients following stem cell transplantation |
| Q80932425 | Chronic lymphocytic leukaemia |
| Q36913228 | Chronic lymphocytic leukemia: biology and current treatment |
| Q35382716 | Chronic lymphocytic leukemia: treatment options for patients with refractory disease |
| Q37212915 | Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia |
| Q82527661 | Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta‐analysis |
| Q43242768 | Current and emerging treatments for chronic lymphocytic leukaemia |
| Q37447307 | Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia |
| Q39996013 | Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study |
| Q60635004 | Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation |
| Q37119402 | Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning |
| Q44477117 | Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients |
| Q30543777 | Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial |
| Q36223667 | Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia |
| Q37445265 | Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation |
| Q36745408 | Graft-versus-leukemia in chronic lymphocytic leukemia |
| Q24616084 | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines |
| Q38155343 | Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors |
| Q38098957 | Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies |
| Q36654926 | Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. |
| Q36460415 | Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome |
| Q36219840 | Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. |
| Q34449575 | Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease |
| Q35563832 | Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure |
| Q39676539 | Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients. |
| Q81100907 | Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial |
| Q36092009 | Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. |
| Q46077879 | Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. |
| Q85234095 | Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia |
| Q34348572 | Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review |
| Q37824996 | Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia |
| Q24642921 | Stem cell transplantation in chronic lymphocytic leukemia |
| Q62735936 | The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis |
| Q84725662 | The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry |
| Q36962654 | The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia |
| Q37439565 | The role of stem cell transplantation in the management of chronic lymphocytic leukaemia |
| Q36346370 | Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies |
| Q37738522 | Transplantation in chronic lymphocytic leukemia |
| Q34978317 | Treatment of fludarabine-refractory chronic lymphocytic leukemia |
| Q36612587 | Treatment options for high-risk chronic lymphocytic leukaemia |
| Q36634599 | Update on risk-stratified management for chronic lymphocytic leukemia |